KK Stock / Shutterstock.com
15 October 2024NewsAmericasMuireann Bolger

Novo Nordisk targets Canada’s largest generics maker over diabetes drug

Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
11 September 2024   Danish multinational asks Delaware court to block semaglutide generics from Sun Pharma and Mylan | ANDAs infringe two claims of patent granted in July, Novo claims.
Big Pharma
12 July 2024   As the popularity of weight-loss drugs like Ozempic soars, the Danish company has to manage seasoned criminals and international investigations to get results, finds Marisa Woutersen.